The Mylan-Strides deal will be the third-largest acquisition in the pharma sector after the Daichii-Ranbaxy ($4.6 billion in June 2008) and Abbott-Piramal ($3.72 billion in September 2010) deals.
Sources said the CCI finding that the Mylan-Strides deal wont have any appreciable adverse impact on competition in India since both firms have insignificant presence in the relevant Indian market would come handy for the FIPB to clear the proposal. The CCI vets M&As for their potential adverse effect on competition based on criteria of turnover and assets of the merging entities to assess the combined entitys market strength. It, however, has a special (more intrusive) dispensation for mergers in the pharmaceutical sector, given the concerns and inter-ministerial scuffles over how to regulate brownfield FDI in this sector.
US pharma giants are showing an active interest in Indian injectables producers given the shortage in their home market after a regulatory crackdown on some of the major local manufacturers. Strides is known for its world-class manufacturing facilities and is a major player in the US too.
Sources said that with both Mylan and Agila having a small presence in the domestic injectables market, the DIPP also may not have any problems with the FIPB approving the deal. The DIPP insists on rigorous regulatory assessment of brownfield pharma FDI proposals as it fears that these could result in not only higher prices of medicines but also shortage of essential products in many therapeutic areas.
While India allows 100% FDI in the pharma sector, any foreign investment in existing pharma companies requires an FIPB nod.
Meanwhile, the FIPB will take up a total of 10 pharma M&A proposals in its meeting next week which includes a share transfer proposal by Total Prosthetics & Onthotics and another share transfer between Mauritius based-Castleton Investment and GlaxoSmithKline. Other proposals before the board include those by Ferring Therapeutics, Hyderabad based-Verdant Life Sciences, Symbiotic Pharmalab, Curadev Pharma, Soothe Healthcare, Lotus Surgical Specialties and Invida India. Other brownfield investment deals which are still pending with the FIPB include that of Mumbai-based Erica Healthcare and Karnataka-based Sutures India.
In December last year, when the FIPB cleared six brownfield pharma FDI proposals worth Rs 1,850 crore, a decision was taken after inter-ministerial consultations that all such projects will also be vetted by the CCI (the special CCI dispensation for pharma M&As needs an amendment to the Competition Act and this proposal is pending with the parliamentary standing committee). Foreign investment in existing pharma facilities came under the spotlight following acquisitions of some major domestic companies such as Ranbaxy, Shanta Biotech and Piramal Health Cares domestic formulations business by multinational firms.
The DIPP, which had earlier pushed for only up to 49 % FDI in existing domestic pharma firms, is now planning to send a detailed proposal to the Prime Ministers Office (PMO) seeking a review of the policy. The department wants more riders (like specified manufacturing and R&D investment commitments by the foreign investor and the market strength of the parties concerned) even as it would now be ready to put up with 100% brownfield FDI in the sector.